Ellen R Strahlman has bought stock on 3 days since Aug 2022

Dr. Ellen R. Strahlman is a director of Altria Group, Inc. (NYSE: MO) and a retired global healthcare executive with extensive experience in medical technology and biopharmaceuticals.( She joined Altria’s Board of Directors on November 2, 2020 and currently serves as Chair of the Innovation Committee and as a member of the Executive, Finance, and Nominating, Corporate Governance and Social Responsibility Committees.( As a non‑employee director, she has reported multiple equity-related transactions in Altria stock, including routine director compensation grants and an open‑market sale of 2,000 shares on May 26, 2026, after which she directly held 25,102 shares of Altria common stock plus additional deferred stock and phantom stock units under company compensation plans.(

Prior to joining Altria’s board, Dr. Strahlman served as Executive Vice President, Research & Development and Chief Medical Officer at Becton, Dickinson and Company from April 2013 until her retirement in January 2018.( Before that, she was Senior Vice President and Chief Medical Officer at GlaxoSmithKline from 2008 to 2012 and later Senior Advisor to the CEO from 2012 to 2013.( Earlier in her career, she held senior leadership roles in global product development, commercialization, medical affairs and business development at major healthcare companies including Pfizer, Novartis, Virogen, Bausch & Lomb and Merck.( She also serves as a director of Hyperion DeFi, Inc. (NASDAQ: HYPD) and previously served on the boards of Syncona Limited and Syncona Partners, LLP, bringing significant board and scientific oversight experience to Altria.( Public sources describe her as holding the title Dr., indicating a medical or doctoral qualification, although specific degree details are not listed in the cited materials.(

Written by Perplexity from public sources.